PDNO
/ Attgeno
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
August 01, 2023
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Attgeno AB | N=16 ➔ 0 | Recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Cardiovascular • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
August 01, 2023
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
(clinicaltrials.gov)
- P2 | N=12 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023
Surgery • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
January 26, 2023
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
(clinicaltrials.gov)
- P2 | N=12 | Recruiting | Sponsor: Attgeno AB
New P2 trial • Surgery • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
January 19, 2023
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
(clinicaltrials.gov)
- P1/2 | N=16 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Aug 2022 ➔ May 2023 | Trial primary completion date: Jul 2022 ➔ Mar 2023
Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
June 21, 2022
A First-in-human Study to Assess the Safety and Tolerability of PDNO
(clinicaltrials.gov)
- P1 | N=34 | Completed | Sponsor: Attgeno AB | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
February 15, 2022
A First-in-human Study to Assess the Safety and Tolerability of PDNO
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Dec 2021 ➔ Jul 2022 | Trial primary completion date: Nov 2021 ➔ May 2022
Trial completion date • Trial primary completion date • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
February 15, 2022
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH
(clinicaltrials.gov)
- P1/2 | N=16 | Recruiting | Sponsor: Attgeno AB | Trial completion date: Aug 2021 ➔ Aug 2022 | Trial primary completion date: Jul 2021 ➔ Jul 2022
Trial completion date • Trial primary completion date • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
May 20, 2021
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH
(clinicaltrials.gov)
- P1/2; N=16; Recruiting; Sponsor: Attgeno AB; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
May 18, 2021
A First-in-human Study to Assess the Safety and Tolerability of PDNO
(clinicaltrials.gov)
- P1; N=48; Recruiting; Sponsor: Attgeno AB
Clinical • New P1 trial • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
1 to 9
Of
9
Go to page
1